Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Thrombocytopenia Warrants Clinical Attention in Hospitalized Patients with Sarcoidosis

  • Guy Dumanis1,2
  • Tamir Ofek1,3
  • Adi Gubbay1,3
  • Coral Tal1,3
  • Ilana Moshkovich1,3
  • Noam Klegar1,3
  • Paz Agam Ohayon1,3
  • Noa Tennenhaus1,3
  • Gad Segal1,4
  • Yigal Farkash5
  • Daniel Bendersky5
  • Moria Tzibin5
1 more authors
  • Reut Kassif Lerner4,6
6 affiliations
  1. 1Education Authority, Chaim Sheba Medical Center, Ramat Gan 5262000, Israel
  2. 2Faculty of Healthcare and Medicine, Ariel University, Ariel 40700, Israel
  3. 3Faculty of Medicine, Nicosia University, P.O. Box 24005, Nicosia CY-1700, Cyprus
  4. 4Gray Faculty of Heath Science and Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
  5. 5Medicine Division, Ort Melton School of Science. Bat-Yam 5964712, Israel
  6. 6Department of Pediatric Intensive Care, Safra Children’s Hospital, Chaim Sheba Medical Center, Tel-Hashomer 5265601, Israel
Read full textPDFDOICite

Abstract

Background: Long-term survival in sarcoidosis patients can be predicted by several clinical and laboratory parameters. Hypercalcemia serves as a predominant, negative prognostic factor. In the current study, we aimed to identify other patient characteristics influencing outcomes over a 10-year period. Methods: This was a retrospective analysis of hospitalized sarcoidosis patients in a large, tertiary medical center. Results: During a 10-year period between 2014 and 2024, data from 89 sarcoidosis patients was collected using MDClone data-mining software. Overall, 13 patients suffered from hypercalcemia (median, corrected for blood albumin: 10.3 mg/dL [9.9–10.5] vs. 9.5 [9.2–9.8], p < 0.001). Patients with hypercalcemia had higher rates of renal failure (30.8% vs. 3.9%, p = 0.008), lower platelet counts (median 153 K/mcl [113–170] vs. 230 [190.7–263.5], p < 0.001), lower hemoglobin concentrations (median 10.2 g/dL [10.0–11.3] vs. 12.5 [10.8–13.6], p < 0.01), higher urea blood levels (median 88 mg/dL [46–130] vs. 38.5 [30–47.2], p < 0.001), higher creatinine levels (median 1.48 mg/dL [1.31–1.6] vs. 0.9 [0.76–1.05], p < 0.001), and lower albumin (mean 3.07 g/dL ± 0.47 vs. 3.57 ± 0.56, p = 0.003). Hypercalcemia was associated with lower, post-discharge survival rates (median 4.8 years [2.6–7.3] vs. 7.9 [3.3–12.1], p = 0.045) and higher rates of 3-year, post-discharge mortality (30.8% vs. 7.9%, p = 0.036). Thrombocytopenia was present in six patients (6.7%); four (66.7%) died within three years, compared with six of 83 patients without thrombocytopenia (7.2%; p = 0.001). In univariate analysis, hypercalcemia and thrombocytopenia were both associated with a higher risk of mortality within 3 years (HR = 4.11, 95% CI 1.16–14.57, p = 0.029 and HR = 13.92, 95% CI 3.88–49.93, p < 0.001, respectively). However, in a multivariate analysis, only patient age and thrombocytopenia continued to be associated with a statistically significant higher risk of death (HR = 7.04, 95% CI 1.46–33.99, p = 0.015). Five of the six patients with thrombocytopenia (83.3%) were subsequently diagnosed with hematologic malignancy, months to years after thrombocytopenia was identified. Conclusions: Thrombocytopenia was associated with higher three-year mortality and may represent a clinical warning sign for occult or subsequently diagnosed hematologic malignancy in patients with sarcoidosis.

Related

  1. The pathogenic and clinical characteristics of community-acquired and hospital-acquired co-infection in patients hospitalized with severe fever with thrombocytopenia syndrome
    Cuiping Xia, Cuiping Xia, Zhongle Cheng +5
    Frontiers in Cellular and Infection MicrobiologyPeer-reviewedCC BYFull textInfectious diseaseDOAJ
  2. Ocular sarcoidosis: from clinical signs to targeted interventions
    Thomas El Jammal, Robin Jacquot, Stéphane Abramowicz +5
    Current Opinion in ImmunologyPeer-reviewedCC BYGeneral biologyEpidemiology & public healthHAL
  3. Predominantly mild thrombocytopenia, haematoma expansion and clinical outcomes in intracerebral haemorrhage
    European stroke journalPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Big Food’s Opposition to the French Nutri-Score Front-of-Pack Labeling Warrants a Global Reaction
    Chantal Julia, Serge Hercberg
    American Journal of Public HealthPeer-reviewedLicence not stated26 citedGeneral biologyNutritionHAL
  5. Multimodal imaging and clinical evolution of an optic nerve head granuloma with prominent overlying vessels in ocular sarcoidosis: a case report and literature review
    Jiahao Xiong, Jiyue Tan, Jun Xiao
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textPhysiologyCrossrefEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{dumanis2026thrombocytopenia,
  title = {{Thrombocytopenia Warrants Clinical Attention in Hospitalized Patients with Sarcoidosis}},
  author = {Guy Dumanis and Tamir Ofek and Adi Gubbay and Coral Tal and Ilana Moshkovich and Noam Klegar and Paz Agam Ohayon and Noa Tennenhaus and Gad Segal and Yigal Farkash and Daniel Bendersky and Moria Tzibin and Reut Kassif Lerner},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15208170},
  url = {https://www.mdpi.com/2077-0383/15/20/8170},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Thrombocytopenia Warrants Clinical Attention in Hospitalized Patients with Sarcoidosis
AU  - Guy Dumanis
AU  - Tamir Ofek
AU  - Adi Gubbay
AU  - Coral Tal
AU  - Ilana Moshkovich
AU  - Noam Klegar
AU  - Paz Agam Ohayon
AU  - Noa Tennenhaus
AU  - Gad Segal
AU  - Yigal Farkash
AU  - Daniel Bendersky
AU  - Moria Tzibin
AU  - Reut Kassif Lerner
PY  - 2026
DA  - 2026/10/01
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15208170
UR  - https://www.mdpi.com/2077-0383/15/20/8170
AB  - Background: Long-term survival in sarcoidosis patients can be predicted by several clinical and laboratory parameters. Hypercalcemia serves as a predominant, negative prognostic factor. In the current study, we aimed to identify other patient characteristics influencing outcomes over a 10-year period. Methods: This was a retrospective analysis of hospitalized sarcoidosis patients in a large, tertiary medical center. Results: During a 10-year period between 2014 and 2024, data from 89 sarcoidosis patients was collected using MDClone data-mining software. Overall, 13 patients suffered from hypercalcemia (median, corrected for blood albumin: 10.3 mg/dL [9.9–10.5] vs. 9.5 [9.2–9.8], p < 0.001). Patients with hypercalcemia had higher rates of renal failure (30.8% vs. 3.9%, p = 0.008), lower platelet counts (median 153 K/mcl [113–170] vs. 230 [190.7–263.5], p < 0.001), lower hemoglobin concentrations (median 10.2 g/dL [10.0–11.3] vs. 12.5 [10.8–13.6], p < 0.01), higher urea blood levels (median 88 mg/dL [46–130] vs. 38.5 [30–47.2], p < 0.001), higher creatinine levels (median 1.48 mg/dL [1.31–1.6] vs. 0.9 [0.76–1.05], p < 0.001), and lower albumin (mean 3.07 g/dL ± 0.47 vs. 3.57 ± 0.56, p = 0.003). Hypercalcemia was associated with lower, post-discharge survival rates (median 4.8 years [2.6–7.3] vs. 7.9 [3.3–12.1], p = 0.045) and higher rates of 3-year, post-discharge mortality (30.8% vs. 7.9%, p = 0.036). Thrombocytopenia was present in six patients (6.7%); four (66.7%) died within three years, compared with six of 83 patients without thrombocytopenia (7.2%; p = 0.001). In univariate analysis, hypercalcemia and thrombocytopenia were both associated with a higher risk of mortality within 3 years (HR = 4.11, 95% CI 1.16–14.57, p = 0.029 and HR = 13.92, 95% CI 3.88–49.93, p < 0.001, respectively). However, in a multivariate analysis, only patient age and thrombocytopenia continued to be associated with a statistically significant higher risk of death (HR = 7.04, 95% CI 1.46–33.99, p = 0.015). Five of the six patients with thrombocytopenia (83.3%) were subsequently diagnosed with hematologic malignancy, months to years after thrombocytopenia was identified. Conclusions: Thrombocytopenia was associated with higher three-year mortality and may represent a clinical warning sign for occult or subsequently diagnosed hematologic malignancy in patients with sarcoidosis.
SN  - 2077-0383
ER  -